title: Does herbal medicine reduce the risk of hepatocellular carcinoma?
abstract: Many herbal medicines are effective anti-inflammatory agents and may therefore suppress the development of hepatocellular carcinoma (HCC). Recently, treatment with a single-tablet regimen containing ledipasvir and sofosbuvir resulted in high rates of sustained virologic response among patients with hepatitis C virus genotype 1 infection who did not respond to prior interferon-based treatment. Patients with chronic hepatitis C are expected to receive this treatment worldwide. However, many patients have hepatitis-like fatty liver and nonalcoholic steatohepatitis. A strategy to prevent the development of HCC in this subgroup of patients is urgently required. Whether herbal medicines can suppress the development of HCC remains to be established. However, herbal medicines are effective anti-inflammatory agents and may inhibit the development of HCC. Clinical trials exploring the effectiveness of herbal medicines in the prevention and treatment of HCC are therefore warranted. The current lack of knowledge and of educational programs is a barrier to increasing the use of potentially effective herbal medicines and performing prospective clinical trials.
authors.affiliation: Yasushi Rino, Norio Yukawa, Naoto Yamamoto, Department of Surgery, School of Medicine, Yokohama City University, Yokohama 236-0004, Japan.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Rino
authors.affiliation: Yasushi Rino, Norio Yukawa, Naoto Yamamoto, Department of Surgery, School of Medicine, Yokohama City University, Yokohama 236-0004, Japan.
authors.forename: Norio
authors.initials: N
authors.lastname: Yukawa
authors.affiliation: Yasushi Rino, Norio Yukawa, Naoto Yamamoto, Department of Surgery, School of Medicine, Yokohama City University, Yokohama 236-0004, Japan.
authors.forename: Naoto
authors.initials: N
authors.lastname: Yamamoto
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001562:Benzimidazoles / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis* / Q000517:prevention & control; D002986:Clinical Trials as Topic; D003545:Cysteine / Q000627:therapeutic use; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use; D005234:Fatty Liver / Q000150:complications; D005449:Fluorenes / Q000008:administration & dosage; D005998:Glycine / Q000627:therapeutic use; D006034:Glycyrrhetinic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D019695:Glycyrrhizic Acid / Q000627:therapeutic use; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000821:virology; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000517:prevention & control; D065626:Non-alcoholic Fatty Liver Disease / Q000150:complications; D008517:Phytotherapy; D028321:Plant Preparations / Q000627:therapeutic use*; D000069474:Sofosbuvir / Q000008:administration & dosage; D013607:Tablets
chemical_list: D000893:Anti-Inflammatory Agents; D001562:Benzimidazoles; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D005449:Fluorenes; D028321:Plant Preparations; D013607:Tablets; C063587:juzentaihoto; C461320:shosaiko-to; C586541:ledipasvir; D019695:Glycyrrhizic Acid; C083319:stronger neominophagen C; D003545:Cysteine; D006034:Glycyrrhetinic Acid; D005998:Glycine; D000069474:Sofosbuvir
keywords: Anti-inflammatory; Chronic hepatitis; Hepatocellular carcinoma; Hepatocellular carcinoma prevention; Herbal medicine